Citadel Advisors’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$7.44M Buy
543,196
+353,519
+186% +$4.84M ﹤0.01% 1580
2025
Q1
$2.1M Sell
189,677
-39,108
-17% -$433K ﹤0.01% 2552
2024
Q4
$2.44M Sell
228,785
-13,281
-5% -$141K ﹤0.01% 2403
2024
Q3
$3.07M Buy
242,066
+167,704
+226% +$2.13M ﹤0.01% 2140
2024
Q2
$1.25M Buy
74,362
+2,546
+4% +$42.7K ﹤0.01% 2839
2024
Q1
$1.08M Sell
71,816
-72,063
-50% -$1.08M ﹤0.01% 3109
2023
Q4
$2.16M Buy
143,879
+136,883
+1,957% +$2.05M ﹤0.01% 2329
2023
Q3
$98K Sell
6,996
-40,984
-85% -$574K ﹤0.01% 4851
2023
Q2
$497K Sell
47,980
-29,196
-38% -$302K ﹤0.01% 3650
2023
Q1
$713K Buy
77,176
+28,239
+58% +$261K ﹤0.01% 3507
2022
Q4
$434K Buy
48,937
+35,216
+257% +$312K ﹤0.01% 3991
2022
Q3
$114K Buy
+13,721
New +$114K ﹤0.01% 5066
2021
Q4
Sell
-57,298
Closed -$964K 7220
2021
Q3
$964K Sell
57,298
-11,251
-16% -$189K ﹤0.01% 3821
2021
Q2
$1.05M Buy
68,549
+30,604
+81% +$467K ﹤0.01% 3967
2021
Q1
$739K Buy
37,945
+1,619
+4% +$31.5K ﹤0.01% 4226
2020
Q4
$655K Buy
36,326
+11,367
+46% +$205K ﹤0.01% 3635
2020
Q3
$481K Buy
24,959
+3,966
+19% +$76.4K ﹤0.01% 3533
2020
Q2
$548K Sell
20,993
-47,285
-69% -$1.23M ﹤0.01% 3384
2020
Q1
$1.22M Sell
68,278
-5,405
-7% -$96.4K ﹤0.01% 2673
2019
Q4
$2.46M Sell
73,683
-21,128
-22% -$705K ﹤0.01% 2169
2019
Q3
$2.26M Sell
94,811
-6,994
-7% -$167K ﹤0.01% 2271
2019
Q2
$3.66M Sell
101,805
-67,844
-40% -$2.44M ﹤0.01% 1901
2019
Q1
$6.27M Sell
169,649
-204,683
-55% -$7.56M ﹤0.01% 1425
2018
Q4
$16.1M Buy
374,332
+98
+0% +$4.22K 0.01% 773
2018
Q3
$17.7M Buy
374,234
+53,200
+17% +$2.51M 0.01% 809
2018
Q2
$16M Buy
321,034
+239,676
+295% +$11.9M 0.01% 819
2018
Q1
$4.04M Buy
+81,358
New +$4.04M ﹤0.01% 1409